Lifirafenib

Generic Name: Lifirafenib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₁₇F_₃N_₄O_₃

CAS Number: 1446090-79-4

Unique Ingredient Identifier: 8762XZS5ZF

Background: Lifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor, Adult

Interventions: Drug: Lifirafenib
Drug: mirdametinib

First Posted Date: 2019-04-05

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 105

Registration Number: NCT03905148

Locations: 🇦🇺
The Prince of Wales Private Hospital - Specialist Medical Randwick, Randwick, New South Wales, Australia
🇦🇺
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
🇺🇸
University of California Los Angeles, Santa Monica, California, United States

and more 3 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy